Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients
Sanchez-de la Rosa R, Herrera L, Moreno S

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
18343275

DOI
10.1016/j.clinthera.2008.02.009

Indexing Status
Subject indexing assigned by NLM

MeSH
Adenine /analogs & derivatives /economics /therapeutic use; Anti-HIV Agents /economics /therapeutic use; Antiretroviral Therapy, Highly Active; Benzoxazines /economics /therapeutic use; Cost-Benefit Analysis; Decision Trees; Deoxycytidine /analogs & derivatives /economics /therapeutic use; Drug Costs; Emtricitabine; HIV Infections /drug therapy /economics /virology; HIV-1; Health Care Costs; Health Resources /economics /utilization; Humans; Lamivudine /economics /therapeutic use; Models, Economic; Organophosphonates /economics /therapeutic use; Reverse Transcriptase Inhibitors /economics /therapeutic use; Tenofvir; Time Factors; Treatment Outcome; Zidovudine /economics /therapeutic use

AccessionNumber
22008000787

Date bibliographic record published
09/08/2008